aTYR PHARMA INC (ATYR)
Nasdaq · Biological Products, (No Diagnostic Substances) · Inc. DE
What they're doing
Not enough recent activity to summarise.
Signals, last 12 months
- Insider purchaseSCHIMMEL PAUL (director) bought $50k of stock
- Insider purchaseSCHIMMEL PAUL (director) bought $299k of stock
- Insider purchaseSCHIMMEL PAUL (director) bought $614k of stock
Insider transactions
| Date | Insider | Role | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-27 | SCHIMMEL PAUL | director | P | 100,000 | 0.5 | $50,000 |
| 2026-02-04 | Shukla Sanjay | director | S | 3,745 | 0.98 | $3,670 |
| 2026-02-04 | Broadfoot Jill Marie | officer | S | 1,558 | 0.98 | $1,527 |
| 2026-02-04 | DENYES NANCY | officer | S | 1,118 | 0.98 | $1,096 |
| 2026-02-03 | Shukla Sanjay | director | M | 10,375 | — | — |
| 2026-02-03 | Broadfoot Jill Marie | officer | M | 3,750 | — | — |
| 2026-02-03 | DENYES NANCY | officer | M | 2,687 | — | — |
| 2025-10-09 | SCHIMMEL PAUL | director | P | 317,999 | 0.94 | $298,919 |
| 2025-10-08 | SCHIMMEL PAUL | director | P | 682,001 | 0.9 | $613,801 |
| 2025-03-17 | Gross Jane A | director | P | 3,750 | 4 | $15,000 |
| 2025-02-04 | Broadfoot Jill Marie | officer | S | 1,254 | 3.78 | $4,740 |
| 2025-02-04 | DENYES NANCY | officer | S | 899 | 3.78 | $3,398 |
| 2025-02-03 | Shukla Sanjay | director | M | 10,375 | — | — |
| 2025-02-03 | Broadfoot Jill Marie | officer | M | 3,750 | — | — |
| 2025-02-03 | DENYES NANCY | officer | M | 2,687 | — | — |
| 2024-07-24 | SCHIMMEL PAUL | director | P | 52,300 | 1.93 | $100,939 |
| 2024-07-23 | SCHIMMEL PAUL | director | P | 6,648 | 1.82 | $12,099 |
| 2024-07-22 | SCHIMMEL PAUL | director | P | 41,052 | 1.74 | $71,430 |
Federal contracts
No federal contract actions on record for this recipient mapping.
Lobbying
No federal lobbying filings on record for this client mapping.
Public attention
7-day average 5 views/day vs 90-day median 4.